Research programme: quiescent cancer therapeutics - Selvita/Felicitex TherapeuticsAlternative Names: Cancer quiescence kinase inhibitors - Felicitex Therapeutics/Selvita; Cancer quiescence kinase inhibitors - Selvita/Felicitex Therapeutics
Latest Information Update: 12 Nov 2014
At a glance
- Originator Felicitex Therapeutics; Selvita
- Mechanism of Action Protein kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Haematological malignancies; Solid tumours
Most Recent Events
- 07 Nov 2014 Early research in Haematological malignancies in USA & Poland (unspecified route)
- 07 Nov 2014 Early research in Solid tumours in USA & Poland (unspecified route)